middle.news
Imagion Clears Ethics Hurdle for MagSense HER2 Trial
9:57am on Wednesday 30th of September, 2026 AEST
•
Biotechnology
Read Story
Imagion Clears Ethics Hurdle for MagSense HER2 Trial
9:57am on Wednesday 30th of September, 2026 AEST
Key Points
Advarra approves the trial protocol, consent forms and study materials
FDA IND clearance and central IRB approval are now in place
Site contracts, investigator training and recruitment planning are underway
Patient enrolment will begin after the first site is activated
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imagion Biosystems (ASX:IBX)
OPEN ARTICLE